
When should a pharma company begin developing the diagnostic that will identify which patients benefit from a new drug? Early enough to avoid costly delays, but not so early that the company limits the possibilities for the drug.
Gulzar Sandhu, Head of Business Development for Biopharma Assay Development at Agilent Technologies, joins us to explore this delicate balance. Companion diagnostics can dramatically improve clinical trial outcomes by identifying patients most likely to respond to a therapy. But developing these tests requires significant investment. Still, to delay can be costly and endanger the entire drug program.
Drawing on Agilent’s experience with PD-L1 assays, Sandhu describes how the companion diagnostic business is evolving. Pharmaceutical companies are increasingly pursuing multiple indications simultaneously, driving up diagnostic development costs. Agilent has set up a lab called Biopharma CDx Services Lab or BCSL with a staged development model that allows companies to begin clinical testing with substantially less investment while preserving a pathway toward full regulatory approval.
Looking ahead, Sandhu discusses the growing importance of antibody-drug conjugates, digital pathology, and multi-omics in identifying new patient populations. First, Sandhu says that the technology Agilent uses for testing comes directly from the biology of the drug candidate. Second, he reminds us that technological sophistication isn’t everything. A diagnostic must ultimately be accessible to patients around the world. “IHC is accessible in every nook and cranny of the world,” he says, explaining why this established technology remains so important even as newer approaches such as DNA and protein sequencing emerge.
The conversation offers a revealing look at how drug development and diagnostic development are becoming increasingly intertwined. Getting that relationship right is central to the future of precision medicine.
D0155698_1.00










